Quetiapine/zolpidem Reactions 1680, p292 - 2 Dec 2017 Parasomnias: case report A female patient [age not stated] developed parasomnia involving episodes of sleep-walking, sleep-talking, sleep- eating and sleep-driving following combined treatment with zolpidem and off-label quetiapine [dosages, routes and time to reactions onset not stated]. The female patient had bipolar I disorder. She was being treated with zolpidem for insomnia (for many years) without parasomnia. During one hospitalisation, zolpidem treatment was switched to quetiapine (off-label setting). She did not have any episode of parasomnia. When she was discharged, zolpidem was added to her quetiapine therapy. Within 2 months after starting this combination therapy, she showed abnormal nocturnal behaviours. She would wake form her sleep, talk to her friends for hours on the phone (sleep-talking), walk to the kitchen to eat (sleep-walking and sleep-eating). She even had episodes of driving out (sleep-driving). She did not recollect any of these events. The female patient’s zolpidem treatment was discontinued and her parasomnia episodes resolved. Clonazepam was added to her quetiapine treatment and her insomnia resolved. She did not have any recurrence of parasomnia later. Author comment: "She presented with parasomnia on a combination of quetiapine and zolpidem." "According to the serotonergic hypothesis of somnambulism, serotonergic neurons can be activated, exert excitatory action on motor neurons and precipitate somnambulism." "Zolpidem is a GABA-A receptor agonist to treat insomnia. Many cases of zolpidem-induced complex sleep behaviors have been reported." Chan C, et al. Complex sleep behaviors in patient treated with quetiapine and zolpidem for insomnia. CNS Spectrums 21: 119-120, No. 1, 22 Feb 2016. Available from: URL: http://doi.org/10.1017/S1092852915000905 [abstract] - USA 803284795 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial